Serving our patients and our people.
We have curated a group of proven leaders with diverse experiences and deep expertise in their respective functions. We are united by a belief in the curative potential of hematopoietic stem cell, or HSC, gene therapy and by our steadfast commitment to making a difference in the lives of individuals and families affected by genetic and other severe diseases.
To me, leading Orchard is an opportunity to change medicine and change the lives of individuals with severe genetic diseases and their families. Through our hematopoietic stem cell platform, cutting-edge science and innovation, and well-executed clinical studies, we can deliver potentially curative therapies for patients. However, the success of our efforts also requires enabling meaningful access to therapy and building the necessary infrastructure across core pillars – regulatory science, manufacturing, diagnostic and commercial capabilities, and education and advocacy – to ultimately deliver on our mission to potentially transform lives.
Bobby is a world-renowned scientist and physician and accomplished strategic and organizational leader with more than 25 years of experience in medicine and biotechnology. As one of Orchard’s principal scientific founders, Bobby serves as chief executive officer of the company, and also sits on Orchard’s board of directors. Bobby has been a pioneer in gene therapy and the evolution of hematopoietic stem cell (HSC) gene therapy technology – including some of the first studies in patients with severe combined immunodeficiency (SCID) – bringing it from some of the first studies in patients to potential regulatory approvals. His unparalleled expertise and deep relationships with key physicians and treatment centers around the world are integral to Orchard’s efforts to identify patients with metachromatic leukodystrophy (MLD) and other diseases through targeted disease education, early diagnosis and comprehensive newborn screening.
Bobby is an honorary professor of pediatrics and immunology at the UCL Great Ormond Street Institute of Child Health and has led multiple clinical trials that have shown that gene therapy can successfully correct the genetic defect in immune deficiencies. He studied medicine and surgery at Kings College in London before completing his Ph.D. at the UCL Great Ormond Street Institute of Child Health.
As a leader in gene therapy, I believe we should be providing innovative solutions across the continuum of a fully integrated company, all while turning groundbreaking innovation into transformative therapies for patients, supporting revolutionary ways to improve access to treatment, and driving long-term growth and value.
Frank brings more than 20 years of experience in the biopharmaceutical industry as an accomplished financial and business executive, with a proven track record of success in leading operations and strategy, corporate finance and commercialization at private and publicly traded biotechnology companies. Frank joined Orchard in 2018 as chief financial officer and chief business officer. Since that time, his role has expanded to president and chief operating officer of Orchard. He also continues to serve as the principal financial officer. In his capacities, Frank creates and drives strategies for overall value-creation and long-term growth of the company. He currently oversees key functional areas for the business, including but not limited to, finance, business development, commercial operations, corporate affairs and quality.
Frank previously served as president and chief operating officer of AMAG Pharmaceuticals (acquired in November 2020 by Covis Group), where he helped develop the business from a single product company in 2011 to one with a portfolio of commercial and development-stage products that generated more than $600 million in sales in 2017. During that time, Frank raised more than $1.8 billion in new capital to support AMAG’s growth strategy. Before joining AMAG, he served as chief operating officer and chief financial officer for Molecular Biometrics, Inc. Earlier in his career, Frank also served as chief executive officer for Critical Therapeutics and chief financial officer for Esperion Therapeutics. Each company completed its initial public offering in the U.S. during his tenure. Frank currently serves on the board of directors of Larimar Therapeutics and Spero Therapeutics.
Frank received his B.B.A. from the University of Michigan, Ann Arbor.
We are building a highly collaborative culture with a deep understanding and appreciation of our diverse talents and collective strengths, and an abiding commitment to our mission to potentially transform the lives of families affected by rare disease.
John brings over 25 years of human resource (HR) leadership experience in the pharmaceutical and biotech industry building high growth, high performance, mission-driven and entrepreneurial companies. Most recently, John served as vice president of human resources and administration for Agenus, where he led the HR function through periods of rapid growth, transformation and global expansion. John played a key role in leading the acquisition and integration of 4-antibody AG and the build-out of the company’s R&D and technical operations capabilities responsible for generating and advancing an immuno-oncology portfolio of over a dozen clinical candidates. Prior to Agenus, John was vice president of global HR for PerkinElmer Life Sciences, during which time the company more than doubled in size and annual sales and significantly expanded its commercial business and operations in the U.S., Europe and APAC regions. Earlier in his career, he spent nearly 10 years with Bristol-Myers Squibb in a series of progressively responsible HR leadership roles including director of HR for corporate staff, director of organizational development for U.S. medicines and head of HR for the oncology and immunology division.
John earned his B.S. in industrial and labor relations from Cornell and his M.A. in organizational psychology from Columbia with a concentration in organizational development. He also completed the global leadership development program at the London Business School.
Nicoletta has extensive experience leading all aspects of technical operations, including process and analytical development, manufacturing, supply chain, engineering and CMC lifecycle management. She joined Orchard Therapeutics from Novartis, where she held positions of increasing responsibility since 2004, most recently serving as global head of cell and gene therapies. In this role, Nicoletta led multidisciplinary international teams responsible for the end-to-end technical development, manufacturing and project management of several gene and cell therapies modalities, including lentiviral, adeno-associated virus (AAV), stem and CAR-T cell processes, from concept to commercialization. She also oversaw the integration of the CAR-T teams and AveXis’ AAV technical capabilities into Novartis’ technical R&D. Previously, Nicoletta was global head of technical development novel biologic entities and cell and gene therapies where she was responsible for the early phase development of biologics and gene therapies. Her broad industry experience encompasses global leadership in the development and manufacturing of sterile drug products and devices and approvals of several commercial assets.
A medicinal chemist by training, Nicoletta began her career in the biopharmaceutical industry as a formulation scientist at Pfizer. She earned her Ph.D. in pharmaceutical technologies from the University of Pavia in Italy. She is a registered pharmacist and member of the UK Royal and Italian Pharmaceutical societies.
Fulvio leads the company’s discovery and translational research activities. In this capacity he will be responsible for expanding the company’s pipeline into larger indications.
He joined Orchard Therapeutics from Smart Immune where he served as chief scientific officer. Previously, Fulvio was senior vice president of translational science at Audentes Therapeutics in San Francisco, where he was responsible for advancing the company’s pipeline from discovery to clinical development overseeing molecular biology, in vivo pharmacology, bioinformatics, and bioanalytics. Prior to joining Audentes, Fulvio was chief scientific officer of Genethon in Évry, France from 2012 to 2017 where he led the development of a robust pipeline of gene therapy programs for blood, liver, and neuromuscular diseases. Earlier in his career, he held various positions at the Center for Regenerative Medicine of the University of Modena, Molmed SpA, Genera SpA, and the San Raffaele-Telethon Institute of Gene Therapy in Milan, Italy.
Fulvio is a member of the Scientific Advisory Board for Kriya Therapeutics. He is also a member of the European Molecular Biology Association, past member of the Board of the American Society of Gene and Cell Therapy and a member of the editorial board of many international journals in the fields of genetics, molecular biology and gene therapy. Fulvio earned a Ph.D. in medical genetics at the University of Rome School of Medicine and has published more than 200 articles in major international journals. He also serves as Professor of Molecular Biology at the University of Modena and Reggio Emilia in Modena, Italy.
Leslie joined Orchard Therapeutics in June 2018 bringing extensive experience leading medical affairs for several premier biopharmaceutical companies. Throughout her career, Leslie led integration of medical functions across brands including publication planning, field team training, advisory boards, patient registry and identification efforts, investigator-initiated trial prioritization and post-marketing planning. A neuroscientist by training, Leslie has dedicated much of her career to advancing new therapies for difficult-to-treat brain diseases.
She joined Orchard Therapeutics from Keryx Biopharmaceuticals (prior to its merger with Akebia Therapeutics) where she served as vice president of medical affairs. She previously served in various positions of increasing seniority in medical affairs at Biogen, where she led key elements of U.S. launch and post-launch activities in multiple sclerosis. In recognition of her success and contributions, Leslie was promoted to leadership roles in Biogen’s multiple sclerosis and then its hemophilia franchises, comprising the company’s approved and investigational therapies. Leslie began her career at Actelion (now part of Janssen) where she supported a variety of therapeutic areas, including respiratory, cardiovascular, rheumatology, neurology and rare disease.
Leslie earned her Ph.D. in neuroscience from Stanford University School of Medicine.
Hematopoietic stem cell gene therapy continues to demonstrate great promise in treating diseases, such as neurodegenerative conditions, that have been historically difficult to address. It’s exciting to work on the cutting edge of medicine, building a commercial organization that aims to bring potentially curative therapies forward to patients in great need.
With more than 20 years of experience in the healthcare and biotech industry, Braden is a seasoned commercial leader with deep expertise in commercial strategy, operations, marketing, and market access. Braden joined Orchard Therapeutics in 2020 as the Senior Vice President and General Manager for North America. Since that time, Braden’s role has expanded to Chief Commercial Officer. In this capacity he is responsible for all commercial strategy and execution for the company, playing a critical role in shaping and achieving Orchard’s global growth strategy.
Prior to joining Orchard, Braden commercialized several rare oncolytic and genetic disorder products during his time at Celgene, NPS Pharma (acquired by Shire for $5.2B) and PTC Therapeutics, where he most recently served as the Vice President and General Manager for the U.S. In this role, Braden led the company’s first U.S. product launch in Duchenne muscular dystrophy and oversaw the strategic planning for their gene therapy business.
Braden received his M.B.A. from New York University Stern School of Business and a B.B.A. from the University of Notre Dame.
Steven brings nearly 20 years of experience building and leading world-class, integrated, translational, value-based health care systems and transformational biotechnology companies. He currently serves as managing director of Healthcare Ventures at Ziff Capital Partners and was previously chair of the board of directors at Spark Therapeutics (acquired by Roche in 2019). In his role at Ziff Capital Partners, Dr. Altschuler co-leads the firm’s efforts toward investing in, and facilitating the start-up and development of, companies with potentially transformative technologies that emphasize cellular and molecular approaches to human disease. He previously co-founded Spark Therapeutics to develop and commercialize the preclinical and clinical gene therapy programs advanced at the Children’s Hospital of Philadelphia (CHOP) and other institutions. He served as Spark’s board chair from its founding through its acquisition in 2019, which included leading the company through a successful transition to a public company and the launch of an approved commercial product, which was the first gene therapy for an inherited disease approved by the U.S. Food and Drug Administration and European Medicines Agency. Dr. Altschuler formerly held chief executive positions at CHOP and University of Miami Health System. He is chairman of the board of directors of 89bio and a member of the board of directors of WW (formerly Weight Watchers International), AsclepiX Therapeutics, ImVaX and Platelet Biogenesis. He is also an independent trustee of the Brigham and Women’s Physician Organization at Mass General Brigham.
Dr. Altschuler holds a B.A. in mathematics and an M.D. from Case Western Reserve University.
Joanne Beck is currently chief technology officer of Aerium Therapeutics. She previously served as chief operating officer at Boston Pharmaceuticals. Prior to that, she was executive vice president of global pharmaceutical development and operations and a member of the executive committee at Celgene. Earlier in her career, she held positions of increasing responsibility in development and operations at Shire, Abbott, Genentech and Amgen. She currently serves on the Board of Directors of Astria Therapeutics.
Joanne earned a B.A. from Lewis and Clark College and a Ph.D. from the University of Oregon Medical School.
John has had an extensive career as a clinician, researcher and drug development executive, bringing industry-leading expertise in advancing novel therapies through research and development and treating patients in need. Most recently, he served as executive vice president of research and development for Portola Pharmaceuticals, where he worked as the lead executive officer for all R&D activities. Prior to joining Portola, John served as chief executive officer at 3-V Biosciences and as president of the Research Institute at Schering-Plough Biopharma (formerly DNAX Research Institute), where he helped progress eight therapeutic candidates into development. He began his biopharmaceutical career at Genentech, where he oversaw their immunology discovery research program. John’s clinical and research experience includes appointments at Massachusetts General Hospital, the Dana-Farber Cancer Institute, University of Michigan Medical School, The Scripps Research Institute and Stanford University School of Medicine. He currently serves on the board of directors of Pliant Therapeutics.
John holds an A.B. in biochemistry and molecular biology from Harvard University and an M.D. and Ph.D. in biological chemistry from Harvard Medical School.
Marc became chief executive officer of Alexion, AstraZeneca’s Rare Disease group, in August 2021 following its acquisition in July. Marc previously served as executive director and chief financial officer of AstraZeneca since November 2013. Marc’s career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel and GSK, has given him extensive industry experience. Marc joined AstraZeneca in 2013, serving as executive vice president, global product and portfolio strategy from June to October 2013. Prior to that, he served as global head of rare diseases at GSK and (concurrently) chairman, GSK Japan. He currently serves on the board of directors of JCR Pharmaceuticals.
Marc earned his MBA from the Hautes Etudes Commerciales and a Bachelor of Law degree from Paris University.
Bobby is a world-renowned scientist and physician and accomplished strategic and organizational leader with more than 25 years of experience in medicine and biotechnology. As one of Orchard’s principal scientific founders, Bobby serves as chief executive officer of the company, and also sits on Orchard’s board of directors. Bobby has been a pioneer in gene therapy and the evolution of hematopoietic stem cell (HSC) technology – including some of the first studies in patients with severe combined immunodeficiency (SCID) – bringing it from some of the first studies in patients to potential regulatory approvals. His unparalleled expertise and deep relationships with key physicians and treatment centers around the world are integral to Orchard’s efforts to identify patients with metachromatic leukodystrophy (MLD) and other diseases through targeted disease education, early diagnosis and comprehensive newborn screening.
Bobby is a professor of pediatrics and immunology at the UCL Great Ormond Street Institute of Child Health and has led multiple clinical trials that have shown that gene therapy can successfully correct the genetic defect in immune deficiencies. He studied medicine and surgery at Kings College in London before completing his Ph.D. at the UCL Institute of Child Health.
Bobby studied medicine and surgery at Kings College in London before completing his Ph.D. at the UCL Institute of Child Health.
Jim is an industry leader with over 30 years of strategic and leadership experience, including more than 20 years as a senior member of executive teams at biotech companies developing and commercializing innovative therapies. Jim is chairman of the board of Pieris Pharmaceuticals, and serves on the boards of Voyager Therapeutics and Fulcrum Therapeutics.
Jim was an entrepreneur-in-residence at Third Rock Ventures, a leading biotech venture and company formation fund, from 2013-2016. He previously served as senior vice president, North America strategy and business development at Sanofi, which he joined upon its acquisition of Genzyme. Jim spent over 20 years at Genzyme, where his roles included senior vice president of international development, president of Genzyme Europe, and founding president and CEO of Genzyme Transgenics Corporation. He started his career in healthcare strategy consulting at Bain and Company.
A graduate of Yale Law School, Jim holds an M.S. from the University of Pennsylvania and a B.A. from Georgetown University.
Charles is a strategic advisor and board member for multiple biotech companies including Orchard Therapeutics, where he brings more than 30 years of biopharmaceutical industry experience. Charles was most recently the president and chief executive officer of Aurinia Pharmaceuticals, a clinical-stage pharmaceutical company focused on the global lupus nephritis market. Prior to Aurinia, he served as vice president and chief financial officer of ViroPharma, during which time the company grew into a global biopharmaceutical rare diseases business before being acquired by Shire plc. Charles has held finance, operational and executive positions at Endo, Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia, Novartis and Bristol-Myers Squibb, and serves as a member of the board of directors for Nabriva Therapeutics, Viking Therapeutics and Generation Bio.
Charles holds an MBA from Rutgers University and a B.S. from Saint Joseph’s University.
Alicia has more than 25 years of life sciences leadership and commercial product expertise, with a particular focus in rare disease and other areas of unmet need. Alicia currently serves as president and chief executive officer of Atalanta Therapeutics, a biotechnology company pioneering new treatment options for neurodegenerative diseases. Prior to Atalanta, Alicia served as president and chief executive officer at Juniper Pharmaceuticals, a diversified public healthcare company, where she led the successful turnaround strategy for the company resulting in a sale to Catalent in August 2018. Prior to her role at Juniper, Alicia held a number of leadership positions in the life sciences industry, including chief commercial officer at Zafgen, senior vice president and chief operating officer at Synageva BioPharma, and roles of increasing responsibility at Genzyme, including serving as vice president and general manager of the metabolic disease division, a business with multiple commercial products, including two orphan drugs. Alicia is also a member of the board of directors at G1 Therapeutics.
Alicia received her B.S. in health administration from the University of New Hampshire and an MBA from Northeastern University.